High EASIX score is an independent predictor of non-relapse mortality in patients with CMML undergoing allogeneic stem cell transplant

© The Author(s) 2022

TO THE EDITOR:

Chronic myelomonocytic leukemia (CMML) is a chronic, clonal disorder, of monocytes. A diagnosis of CMML requires that monocytes comprise at least 10% of the peripheral blood white blood cell differential with a sustained absolute monocyte count of $\geq 1 \times 10^9$ cells/L, and the absence of other disease-defining genetic abnormalities, such as BCR-ABL1, PDGFRα, PDGFRβ, FGFR1, or PCM1-JAK2 fusions [1].

Allogeneic stem cell transplant (alloSCT) remains the only curative option for patients with CMML and studies evaluating alloSCT outcomes have shown treatment-related mortality ranging from 12 to 52% [2–8]. It was recently shown that the endothelial activation and stress index (EASIX) score could also predict mortality after alloSCT [9]; however, its value is limited to AML and MDS.

The goal of our study was to assess if pre-conditioning EASIX can predict non-relapse mortality (NRM) in patients with CMML undergoing alloSCT.

Patients with CMML who underwent an alloSCT at Mayo Clinic between November 1992 and October 2021 were included. EASIX score was calculated using the formula: lactate dehydrogenase (LDH (U/L)) × Creatinine (mg/dL) / platelet count (10^9/L) and analyzed based on log2-transformed values. The LDH, creatinine, and platelet values available on the day of or prior to starting conditioning therapy, within 45 days of alloSCT, were used for calculation of the EASIX score (Fig. 1a). We divided the log2-EASIX scores into quartiles and evaluated the log2-EASIX quartile cut-offs for their impact on NRM. Patients with an HCT-CI score ≥3 were considered to have high HCT-CI scores. The cumulative incidence of NRM was determined using competing risk analyses, with relapse considered as a competing risk event. Further details of the method description are provided in the Supplementary materials.

A total of 68 patients (68% males) were evaluated for the purposes of the study. Median age at diagnosis was 60 years (range: 18–73 years). Thirty-two (47.1%) patients had dysplastic subtype of CMML, while 36 (52.9%) patients had proliferative type of CMML.

Seventeen (25%) patients had progressed to CMML blast phase before alloSCT. A total of 57 (83.8%) patients had received some treatment for CMML before alloSCT (Supplementary Table 1).

Eighteen (26.5%) patients were in complete remission at the time of alloSCT.

At transplant, the median age for the entire cohort was 61 years (range: 18–73 years). The median time of follow-up was 5.5 years (95% CI 5–12.3 years) and at last follow-up a total of 25 (36.8%) patients were alive. The median OS was 3.2 years (95% CI 1.37–13.6 years). The cumulative incidence of NRM for the entire cohort was 7.4%, 19.1%, 26.7% at 100 days, 1 year, and 3 years post alloSCT, respectively. The median log2-EASIX score was 0.89 (range $-2.29$ to 5.91). Upon analyzing log2-EASIX values by quartiles, the 75th percentile log2-EASIX score of 2.32 was most optimally correlated with 3-year NRM and OS post alloSCT. Accordingly, 17 (25%) patients had a high log2-EASIX score and 51 (75%) had a low log2-EASIX score. While 26 (38.2%) patients had alloSCT before the year 2011, the proportion of patients with high EASIX scores was not significantly different between those undergoing alloSCT before or after the year 2011 (30.8% vs. 21.4%, $P = 0.56$) (Supplementary Table 2).

The cumulative incidence of NRM among patients with high EASIX score was significantly higher compared to those with low EASIX score at 100 days (23.5% vs. 2.0%, $P = 0.003$), at 1 year (41.2% vs. 11.8%, $P = 0.007$) and at 3 years (52.9% vs. 17.9%, $P = 0.003$) after alloSCT (Fig. 1b).

There was no significant difference in relapse rates between patients with high versus low EASIX score at 100 days (11.8% vs. 15.7%, $P = 0.72$) at 1 year (17.6% vs. 29.4%, $P = 0.37$) and at 3 years (17.6% vs. 31.5%, $P = 0.31$) after alloSCT (Fig. 1b). Graft-versus-host disease (3 patients, 17.6%) and infection (3 patients, 17.6%) were the most common causes of NRM among patients with high EASIX scores (Supplementary Table 3).

A total of 66 patients were evaluated for HCT-CI score, of whom 30 (45.5%) had a high HCT-CI score. The median HCT-CI score was 2 (range: 0–8). NRM after alloSCT among patients with high HCT-CI score was not statistically different compared to those with low HCT-CI scores at 100 days (10% vs. 5.6%, $P = 0.51$), at 1 year (30% vs. 11.1%, $P = 0.06$), and at 3 years (33.3% vs. 23%, $P = 0.28$) after alloSCT (Fig. 1c).

Patients with a high log2-EASIX score had a worse 3-year OS (29.4% vs. 57.4%, $P = 0.017$, Supplementary Fig. 1a), further reflecting the significant association of high EASIX score with NRM. There was a trend towards worse 3-year OS among patients with high compared to low HCT-CI scores (3-year OS rate 39% vs. 59.4%, $P = 0.056$, Supplementary Fig. 1b).

The univariate cox-proportional hazard model showed that an increasing log2-EASIX score, when analyzed as a continuous variable, adversely affected the 3-year post-alloSCT survival (HR 1.41, 95% CI 1.1–1.81, $P = 0.007$).
A high EASIX score pretransplant was able to predict NRM at 100 days, 1 year, and 3 years after alloSCT. The strength of EASIX score is its simplicity and ease of calculation. Therefore, EASIX calculated during pretransplant evaluation can be a simple, yet strong, tool to ascertain the risk of NRM.

Limitation of our study is that it is a retrospective analysis with a small sample size. However, given that CMML has a lower incidence, most of the single-institution studies are limited by a small sample size.

In summary, this is the first study assessing the predictive power of EASIX score for NRM in patients with CMML undergoing alloSCT. Our study suggests that a log₂-EASIX score ≥2.32 is an independent predictor of increased risk of NRM after alloSCT, irrespective of HCT-CI score. Patients with high log₂-EASIX score at pretransplant evaluation should be carefully evaluated due to the high risk of associated NRM after transplant. Due to the small sample size, larger retrospective studies are required to validate our findings.

Anmol Baranwal1, Abhishek Mangaonkar1, Mithun V. Shah1, Mark R. Litzow1, William J. Hogan1,2, Minial M. Patnaik1,1 and Hassan B. Alkhateeb1

1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA. Email: Alkhateeb.Hassan@mayo.edu

DATA AVAILABILITY
The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.

REFERENCES
1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.
2. Eissa H, Gooley TA, Sorror ML, Nguyen F, Scott BL, Doney K, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biol Blood Marrow Transplant. 2011;17:908–15.
3. Symeonidis A, van Biezen A, de Wreede L, Picciochi A, Finke J, Beelen D, et al. Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol. 2015;171:239–46.
4. Krishnamurthy P, Lim ZY, Nagi W, Kenyon M, Mijovic A, Ireland R, et al. Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience. Bone Marrow Transplant. 2010;45:1502–7.
5. Ocheni S, Kröger N, Zabelina T, Zander AR, Bacher U. Outcome of allo-SCT for chronic myelomonocytic leukemia. Bone Marrow Transplant. 2009;43:659–61.
6. Elliott MA, Telfer A, Hogan WJ, Letendre L, Gastineau DA, Ansell SM, et al. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant. 2006;37:1003–8.
7. Mittal P, Saliba RM, Giralt SA, Shahjahan M, Cohen A, Karandish S, et al. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplant. 2004;33:1005–9.
8. Kröger N, Zabelina T, Guardiola P, Runde V, Sierra J, van Biezen A, et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2002;118:67–73.
9. Luft T, Benner A, Terzer T, Jodele S, Dandoy CE, Storb R, et al. EASIX and mortality after allogeneic stem cell transplantation. Bone Marrow Transplant. 2020;55:533–61.
10. Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, et al. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015;5:e333.
11. Liu HD, Ahn KW, Hu ZH, Hamadani M, Nishihori T, Wirk B, et al. Allogeneic hematopoietic cell transplantation for adult chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2017;23:767–75.
12. Kerbauy DMB, Chyou F, Gooley T, Somor ML, Scott B, Pagel JM, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2005;11:713–20.

AUTHOR CONTRIBUTIONS
HBA contributed to the study design. AB abstracted the data and did the analysis. AB and HBA wrote the initial draft. AM, MVS, MRL, WJH, and MMP contributed to patient data and reviewed the manuscript. All authors approved the final version of the manuscript.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41409-022-01829-w.

Correspondence and requests for materials should be addressed to Hassan B. Alkhateeb.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.